65,437 trials
Acute Malaria
Primary: Cohort A: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Related TEAEs — 9; 0; 1 Participants
Aging Well
Primary: Learning of Virtual Reality Tasks — 2.13; 2.17; 2.22; 2.22 score on a scale
Cryptococcal Meningitis
Primary: Early Fungicidal Activity — 0.39; 0.28 log10 CFU/mL/day
Dry Eye
Primary: Mean Overall IDEEL SB Score - Group 1 — 45.53; 31.23 score on a scale
UTI
Primary: Eligible Subjects That Were Enrolled in the Study — 70 Participants
Glomerulonephritis, Membranous
Primary: Percentage of Complete Remission — 4; 3 Participants
Healthy Volunteers
Primary: Incidence of Adverse Events (AEs) — 0; 0; 0; 0 participants
Glaucoma Open-Angle Primary · Ocular Hypertension
Primary: Efficacy as Assessed by Change in Intraocular Pressure — -6.3; -6.3; -5.9; -7.0 mmHg
Chronic Spontaneous Urticaria
Primary: Reduction in Urticaria Activity Score (UAS7) — 3; 7 Participants
Homozygous Familial Hypercholesterolaemia (HoFH)
Primary: Efficacy Endpoint: Percent Change in Low-density Lipoprotein Cholesterol (LDL C) at Week 24 Compared to Baseline — -53.910; -56.529; -51.633 Percent change from Baseline…
Hand Osteoarthritis · Wrist Osteoarthritis · Thumb Osteoarthritis
Primary: Change in Pain Intensity (Numerical Rating Scale NRS, Discrete Boxes 0-10, Higher Score Mean Worse Pain) — -1.30 Units on a scale
Asthma, Exercise-Induced
Primary: Maximum Percentage Fall From Post-dose, Pre-exercise Baseline in Forced Expiratory Volume in 1 Second (FEV₁) Observed up to 60 Minutes Post-exercise Challenge — 6.95…
Diabetes Mellitus, Type 2
Primary: All Reported Adverse Events Collected From Subjects Taking at Least One Dose of ESGLITEO® — 26 Number of events
Caregiver Burden
Primary: Feasibility, as Measured by the Percentage of Caregivers Who Enroll in the Study — 37 percentage of all eligible participants
Non-Small Cell Lung Cancer · Solid Tumor
Primary: Overall Response Rate — 50.0; 33.3; 7.9; 0 percentage of participants